Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q4 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript

Mar 08, 2023 / 09:30PM GMT
Release Date Price: €22.4 (+1.82%)
Operator

Good afternoon. Thank you for attending the Mirum Pharmaceuticals Fourth Quarter and Year-end 2022 Financial Results and Business Update. My name is Matt, and I'll be your moderator for today's call. (Operator Instructions)

I would now like to turn the conference over to our host, Andrew McKibben, Vice President of Investor Relations and Finance. Andrew, please go ahead.

Andrew McKibben

Thanks, Matt, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals Fourth Quarter and Full Year 2022 Conference Call. I'm joined today by our President and CEO, Chris Peetz, our Chief Operating Officer, Peter Radovich, our Head of R&D, Pam Vig; and our CFO, Ian Clements.

Earlier today, Mirum issued a news release announcing the company's results for the fourth quarter and full year 2022. Copies of this news release and SEC filings can be found in the Investors section of our website. Full details and updates from the quarter can be found in our news release and 10-K issued today.

Before we begin, I'd like to remind you that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot